For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

Cybercriminals’ tactics have evolved to target sensitive data and disrupt research and development in the pharmaceutical ...

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

After threatening to impose “25% or higher” tariffs on foreign-made pharmaceuticals along with automobiles and semiconductors ...

Evolving regulations in sterile manufacturing requires innovation, market knowledge, and investment. How can drug ...

The API Innovation Center (APIIC) today released an industry white paper detailing the United States’ overreliance on foreign production of essential medicines and presenting a comprehensive plan to ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...

Violations highlight growing concerns over the unchecked rise in medicine prices and their impact on affordability ...

The healthcare industry is experiencing a significant shift with the integration of digital innovations in cold chain ...

The Committee was disturbed to find that prosecutions and arrests remain disproportionately low despite the high detection of ...

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth re ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...